Regimens associated with good response in progressing patients for whom R-CHOP chemotherapy failed
| Reference . | Regimen . | Drug tested . | No. of patients . | ORR (%) . | CR or PR (%) . | PFS . | Toxicity . |
|---|---|---|---|---|---|---|---|
| 143 | Bendamustine-rituximab | Combination, patients not eligible for BMT | 55 | 50 | 28 | 8.8 mo | Moderate |
| 144 | R-GEM-P | 45 | 61 | 22% (3-y) | Neutropenia, thrombocytopenia | ||
| 145 | Bendamustine-rituximab-lenalidomide | Test the addition of lenalidomide | 11 | 5 patients | NA | Neutropenia | |
| 16 | R-ICE/R-DHAP | In patients with MYC rearrangement, 75% with complex hits | 28 | 50 | 18% (4-y) | ||
| 146 | Bortezomib-gemcitabine | Test bortezomib | 16 | 10 | NA | Neutropenia, thrombocytopenia | |
| 147 | R-ICE + dacetuzumab | Phase 3 testing of dacetuzumab (interrupted for futility) | 75 | 67 | 33 | 12.1 mo | Febrile neutropenia |
| 148 | Rituximab + inotuzumab ozogamicin | Inotuzumab ozogamicin | 118 | 74 relapsed, 20 refractory | 17.1 mo | Thrombocytopenia, neutropenia | |
| 149 | R-ICE + lenalidomide | Test lenalidomide with autologous transplant | 15 | 73 | NA | Well tolerated | |
| 150 | Rituximab-gemcitabine + dacetuzumab | Test dacetuzumab | 30 | 47 | 20 | NA | Well tolerated |
| 151 | Bendamustine-rituximab + YM155 | Test YM155, a survivin suppressant in mice | |||||
| 152 | Anti-CD19 CAR-T cells | First report in lymphoma | 15 | 80 | 53 | 11 mo | Fever, hypotension |
| 153 | Alisertib + vincristine-rituximab | In DPL in mice; high synergy between alisertib, vincristine, and rituximab | |||||
| 154 | R-ESHAP + lenalidomide | Test the addition of lenalidomide | 19 | 79 | 47 | 44% (2-y) | Cytopenias |
| 155 | Ofatumumab + ICE/DHAP | Test ofatumumab in place of rituximab | 61 | 61 | 37 | 9.5 mo | Cytopenias, febrile neutropenia |
| 156 | R-P-IMVP16/CBDCA | Retrospective analysis | 59 | 64 | 34.7% (2-y) | Neutropenia, thrombocytopenia | |
| 157 | Vorinostat + CVEP | 23 | 57 | 35 | 9.2 mo | Lymphopenia | |
| 158 | Bendamustine-rituximab | 48 | 45.8 | 15.3 | 3.6 mo | Neutropenia | |
| 159 | CUDC-907 | Phase 1 of this dual inhibitor (HDAC and PI3K) | 44 | 14 | 2 CR; 3 PR | 2.4 mo | Thrombocytopenia, neutropenia, hyperglycemia |
| Reference . | Regimen . | Drug tested . | No. of patients . | ORR (%) . | CR or PR (%) . | PFS . | Toxicity . |
|---|---|---|---|---|---|---|---|
| 143 | Bendamustine-rituximab | Combination, patients not eligible for BMT | 55 | 50 | 28 | 8.8 mo | Moderate |
| 144 | R-GEM-P | 45 | 61 | 22% (3-y) | Neutropenia, thrombocytopenia | ||
| 145 | Bendamustine-rituximab-lenalidomide | Test the addition of lenalidomide | 11 | 5 patients | NA | Neutropenia | |
| 16 | R-ICE/R-DHAP | In patients with MYC rearrangement, 75% with complex hits | 28 | 50 | 18% (4-y) | ||
| 146 | Bortezomib-gemcitabine | Test bortezomib | 16 | 10 | NA | Neutropenia, thrombocytopenia | |
| 147 | R-ICE + dacetuzumab | Phase 3 testing of dacetuzumab (interrupted for futility) | 75 | 67 | 33 | 12.1 mo | Febrile neutropenia |
| 148 | Rituximab + inotuzumab ozogamicin | Inotuzumab ozogamicin | 118 | 74 relapsed, 20 refractory | 17.1 mo | Thrombocytopenia, neutropenia | |
| 149 | R-ICE + lenalidomide | Test lenalidomide with autologous transplant | 15 | 73 | NA | Well tolerated | |
| 150 | Rituximab-gemcitabine + dacetuzumab | Test dacetuzumab | 30 | 47 | 20 | NA | Well tolerated |
| 151 | Bendamustine-rituximab + YM155 | Test YM155, a survivin suppressant in mice | |||||
| 152 | Anti-CD19 CAR-T cells | First report in lymphoma | 15 | 80 | 53 | 11 mo | Fever, hypotension |
| 153 | Alisertib + vincristine-rituximab | In DPL in mice; high synergy between alisertib, vincristine, and rituximab | |||||
| 154 | R-ESHAP + lenalidomide | Test the addition of lenalidomide | 19 | 79 | 47 | 44% (2-y) | Cytopenias |
| 155 | Ofatumumab + ICE/DHAP | Test ofatumumab in place of rituximab | 61 | 61 | 37 | 9.5 mo | Cytopenias, febrile neutropenia |
| 156 | R-P-IMVP16/CBDCA | Retrospective analysis | 59 | 64 | 34.7% (2-y) | Neutropenia, thrombocytopenia | |
| 157 | Vorinostat + CVEP | 23 | 57 | 35 | 9.2 mo | Lymphopenia | |
| 158 | Bendamustine-rituximab | 48 | 45.8 | 15.3 | 3.6 mo | Neutropenia | |
| 159 | CUDC-907 | Phase 1 of this dual inhibitor (HDAC and PI3K) | 44 | 14 | 2 CR; 3 PR | 2.4 mo | Thrombocytopenia, neutropenia, hyperglycemia |
BMT, bone marrow transplantation; CAR, chimeric antigen receptor; CBDCA, carboplatin; CVEP, cyclophosphamide, vincristine, etoposide, and prednisone; PI3K, phosphoinositide 3-kinase; R-GEM-P, rituximab plus gemcitabine, cisplatin, and methylprednisolone; R-P-IMVP16, rituximab, methylprednisolone, ifosfamide, methotrexate, and etoposide.